Method For Storing P1, P4-bis(5'-Uridyl)Tetraphosphate Crystals
20180161355 ยท 2018-06-14
Assignee
Inventors
- Yusuke OHBA (Choshi-shi, Chiba, JP)
- Kentaro MIYOSHI (Choshi-shi, Chiba, JP)
- Fumitaka KANO (Choshi-shi, Chiba, JP)
Cpc classification
C30B29/605
CHEMISTRY; METALLURGY
A61K31/7084
HUMAN NECESSITIES
International classification
A61K31/7084
HUMAN NECESSITIES
Abstract
[Problem] Provided is a method for easily and stably storing crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0 C. or more and less than 25 C.; (2) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P.sup.1, P.sup.4-bis (5-uridyl) tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.
Claims
1. A method for storing packed crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0 C. or more and less than 25 C.; (2) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition so that a rate of decrease in HPLC purity of the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof at four weeks of storage is held to 0.15% or less.
2. A method for storing packed crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (4) to (6): (4) a storage temperature of 0 C. or more and less than 25 C.; (5) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 7.4; and (6) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.2 to 6.2 is selected and the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition so that a rate of decrease in HPLC purity of the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof at four weeks of storage is held to 0.1 A or less.
3. A method for storing packed crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (7) and (8): (7) a storage temperature of 0 C. or more and less than 25 C.; and (8) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.6 to 6.6 is selected and the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition so that a rate of decrease in HPLC purity of the crystals of P.sup.1, P.sup.4-bis(5-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof at four weeks of storage is held to 0.05% or less.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0009]
DESCRIPTION OF EMBODIMENTS
[0010] The storage method according to the present invention relates to a method for storing UP.sub.4U crystals. UP.sub.4U for use as crystals may be in the form of a free base or a pharmaceutically acceptable salt. Specific examples of the salt are pharmaceutically acceptable salts, including alkali metal salts, such as sodium salts and potassium salts, alkaline earth metal salts, such as calcium salts and magnesium salts, and ammonium salts. Examples of the salt in terms of number of hydrogens substituted include those obtained by substitution with one to four metal atoms.
[0011] In the storage method according to the present invention, in order to hold the rate of change in HPLC purity of UP.sub.4U crystals at four weeks of storage to 0.15% or less, the UP.sub.4U crystals are stored under one of the following conditions (1) to (3): (1) a storage temperature of 0 C. or more and less than 25 C.; (2) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.0 to 6.4.
[0012] Furthermore, in the storage method according to the present invention, in order to hold the rate of change in the HPLC purity of the UP.sub.4U crystals at four weeks of storage to 0.10% or less, the UP.sub.4U crystals are stored under one of the following conditions (4) to (6) : (4) a storage temperature of 0 C. or more and less than 25 C.; (5) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 7.4; and (6) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.2 to 6.2.
[0013] Moreover, in the storage method according to the present invention, in order to hold the rate of change in the HPLC purity of the UP.sub.4U crystals at four weeks of storage to 0.05% or less, the UP.sub.4U crystals are stored under one of the following conditions (7) and (8) : (7) a storage temperature of 0 C. or more and less than 25 C.; and (8) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.6 to 6.6.
[0014] The term crystal pH in the present invention refers to the value of pH of crystals measured with 1 g of crystals dissolved in 20 mL of water. The control of the pH of UP.sub.4U crystals within a desired range of values is possible, for example, by controlling the pH of an original solution for use in crystallization. To control the pH, it is sufficient to use, as necessary, an arbitrary acid or alkali capable of being used for production of raw materials or the like for pharmaceutical products. An arbitrary one selected from hydrochloric acid, nitric acid, phosphoric acid, and so on can be used as the acid and an arbitrary one selected from sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, and so on can be used as the alkali.
[0015] UP.sub.4U for use in the present invention can be synthesized and crystallized by any known method (for example, Patent Literature 1). In a specific example, UP.sub.4U crystals can be obtained by synthesizing crude UP.sub.4U by an arbitrary production method, such as chemical synthesis or enzymatic synthesis, refining the crude UP.sub.4U using anion-exchange chromatography and activated carbon chromatography, and adding a hydrophilic organic solvent into a solution of the refined UP.sub.4U. However, the crystals may be those obtained by other methods so long as the crystals can be obtained. Furthermore, the obtained crystals can be appropriately dried by an ordinary method, such as reduced-pressure drying, through-circulation drying or drying by heating.
[0016] Considering that the obtained UP.sub.4U crystals are for use in pharmaceutical products, they have preferably a purity of 95% or more, more preferably 97% or more, and still more preferably 99% or more. Furthermore, these crystals may carry adhering water or may be a hydrate. More specifically, three to eight molecules of water may bind or adhere to one molecule of UP.sub.4U.
[0017] In the method according to the present invention, the UP.sub.4U crystals are stored in a state packed in an arbitrary container. The container that can be used for storage is a container having an arbitrary shape, such as a pouch, a bottle, a can, a box, an ampule.
[0018] Materials for the container that can be used include unstretched, uniaxially or biaxially stretched films made of polyolefin resins, such as low-density polyethylenes and high-density polyethylenes, vinyl resins, such as polystyrene and polyvinyl chloride, polyamide resins, such as nylon 6 and nylon 66, polyester resins, such as polyethylene terephthalate and polytetramethylene terephthalate.
[0019] These film materials can be used in a single layer or a laminate formed of two or more layers or can be used in a laminate of metal foils, such as aluminum, or a laminate of deposited metal or metal oxide films. Furthermore, the container may be stored in a two-ply, three-ply or more multi-ply form. The packing state of the container is preferably a non-open state, such as closed, airtight or sealed state, and more preferably a sealed or airtight state.
[0020] If UP.sub.4U is stored under conditions where the crystal pH or the temperature is out of the above ranges, UP.sub.4U becomes likely to decompose, which causes the risk that UP.sub.4U becomes unsuitable when used as raw materials or the like for pharmaceutical products.
[0021] The method according to the present invention can hold the decrease in high-performance liquid chromatography (HPLC) purity of UP.sub.4U at four weeks of storage to 0.15% or less, 0.10% or less, or even 0.05% or less, which is extremely suitable for suppressing decomposition.
[0022] Specifically, for example, when in storing UP.sub.4U the decrease in HPLC purity of UP.sub.4U as active ingredients for production of pharmaceutical products is required to be less than 0.15%, UP.sub.4U is stored in a closed, sealed or airtight state under one of the following storage conditions: (1) a storage temperature of 0 C. or more and less than 25 C.; (2) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.0 to 6.4. So long as UP.sub.4U is in a storage environment where the storage temperature can be controlled at 0 C. or more and less than 25 C., there is no need to control the crystal pH. However, when the temperature of the storage environment is not stable and may reach 25 C. or more and less than 40 C., the crystal pH needs to be controlled at 4.5 to 7.4 in order to hold the decrease in HPLC purity of UP.sub.4U at four weeks of storage to less than 0.15%. When the above temperature may further increase to 40 C. or more and less than 60 C., the crystal pH is controlled at 5.2 to 6.2.
[0023] Likewise, in order to hold the decrease in HPLC purity of UP.sub.4U to less than 0.10%, UP.sub.4U needs to be stored under one of the following storage conditions: (4) a storage temperature of 0 C. or more and less than 25 C.; (5) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 7.4; and (6) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.2 to 6.2.
[0024] Furthermore, in order to hold the decrease in HPLC purity of UP.sub.4U to less than 0.05%, UP.sub.4U is stored under one of the following storage conditions: (7) a storage temperature of 0 C. or more and less than 25 C.; and (8) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.6 to 6.6.
[0025] Taken together, (A) when the storage temperature is kept at 0 C. or more and less than 25 C., substantially no decrease in HPLC purity of UP.sub.4U crystals occur regardless of the crystal pH of UP.sub.4U and, therefore, this condition is suitable for long-term storage of the UP.sub.4U crystals. On the other hand, in order to store UP.sub.4U crystals under an environment where the temperature control is difficult, it is necessary to control the crystal pH within a specified range by controlling the pH of the original solution of the crystals.
[0026] (B) When the storage temperature may reach 25 C. or more and less than 40 C., the crystal pH is set at 4.5 to 8.0, preferably 4.5 to 7.4, and more preferably 4.6 to 6.6. This is preferred because the decrease in HPLC purity of the crystals at four weeks of storage can be thus held to 0.15% or less, 0.10% or less, and 0.05% or less, respectively.
[0027] (C) When the storage temperature may reach 40 C. or more and less than 60 C., the decrease in HPLC purity of the crystals at four weeks of storage can be held to 0.15% or less and 0.10% or less by setting the crystal pH at 5.0 to 6.4 and preferably 5.2 to 6.2, respectively. When it is necessary to hold the decrease in HPLC purity to 0.05% or less, a storage temperature exceeding 40 C. is not preferred.
[0028] (D) Furthermore, reaching a storage temperature of 60 C. or more is not preferred because the HPLC purity of the crystals may significantly decrease regardless of the crystal pH.
[0029] Moreover, in order to hold the decrease in HPLC purity of UP.sub.4U crystals to a desired value or less when they are stored for more than four weeks (two or three months), it is necessary to set the storage temperature at 0 C. or more and less than 25 C. or set the crystal pH within more preferable ranges of crystal pHs than within the ranges thereof described to be necessary for the respective temperature regions in the above (B) and (C).
EXAMPLES
[0030] Hereinafter, the present invention will be described in specific terms with reference to examples but is not at all limited to these examples.
[0031] (Example 1) Control of UP.sub.4U Crystals with Different pHs UP.sub.4U crystals prepared by a known method were dissolved in deionized water. Various phosphoric acid aqueous solutions or sodium hydroxide aqueous solutions were each added to the solution containing UP.sub.4U dissolved therein to prepare solutions having different pHs (hereinafter, referred to as original solutions).
[0032] Ethanol was put into each of the original solutions to make the original solution lightly cloudy, followed by addition of a small amount of UP.sub.4U crystals and stirring for a dozen hours. After confirmation of crystal precipitation, ethanol was further put into each of the solutions, the solution was stirred, and crystals were then separated from the solution using a centrifuge. The obtained various crystals were dried with a circulation dryer to prepare various UP.sub.4U crystals having different pHs.
[0033] (pH Measurement) Water was sufficiently boiled and then cooled in a state where a carbon dioxide absorption tube was connected, thus preparing distilled water. An amount of 1.0 g of each test sample was dissolved in 20 mL of the prepared distilled water. The pH (crystal pH) of this solution was measured. Table 1 below shows the correspondences between the pHs of the original solutions prepared before being crystallized and the crystal pHs.
TABLE-US-00001 TABLE 1 Orginal Liquid pH 2.50 3.00 3.50 4.00 5.50 6.50 7.40 7.80 8.00 8.10 8.20 Crystal pH 4.60 5.16 5.54 5.64 5.97 6.32 6.66 6.91 7.12 7.43 7.97
(Example 2) Stability Test
[0034] (Packing of Test Sample) An amount of approximately 20 mg of each test sample was put into a pouch made of low-density polyethylene and sealed by heat sealing. This pouch was further put into a pouch made of low-density polyethylene and sealed by heat sealing. This pouch was still further put into a pouch made of low-density polyethylene and sealed by heat sealing. This pouch was put into a pouch made of aluminum-metallized film and sealed by heat sealing, thus preparing a sample for stability test.
[0035] (Stability Test) Packed samples were put into thermostatic baths at 5 C., 25 C., 40 C., and 60 C., respectively, and stored for four weeks.
[0036] (Analysis) For each sample zero days after the start of the stability test and samples of the same type at four weeks of storage at the different temperatures, the packing by sealing was opened and each of the test samples was dissolved in deionized water. This solution was analyzed by HPLC and, based on the analysis result, evaluated in terms of stability. The conditions of the measurement using HPLC in this analysis were as follows.
TABLE-US-00002 TABLE 2 System Waters 2695,2487 Column Zorbax Eclipse XDB-C18, S-5 um, 250 4.6 mmI.D. Guard Column Zorbax Eclipse XDB-C18 12.5 4.6 mm Temperature 30 C. Measurement 262 nM Wavelength Flow 1.0 mL/min. Mobile Phase MeOH/Buffer = 16/84 Buffer 10 mM TBA-HSO4 (3.4 g/L) 80 mM KH2PO4 (10.89 g/L) pH 6.7 0.1 by KOH (2.2 g/L)
The evaluation was made by defining the value obtained by subtracting the HPLC purity (%) of crystals zero days after the start of the stability test from the HPLC purity (%) of the crystals at four weeks of storage as a rate of change (%). The rate of changes (%) under the different conditions are shown in Table 3 and
TABLE-US-00003 TABLE 3 pH 4.60 5.16 5.54 5.64 5.97 6.32 6.66 6.91 7.12 7.43 7.97 5 C. 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.03 25 C. 0.01 0.02 0.02 0.01 0.02 0.01 0.03 0.02 0.02 0.01 0.01 40 C. 0.05 0.04 0.03 0.02 0.03 0.02 0.04 0.04 0.08 0.15 0.12 60 C. 0.25 0.08 0.07 0.07 0.08 0.14 0.18 0.24 0.46 0.50 0.87
[0037] As seen from the results of Table 3 and
[0038] Furthermore, it became obvious that the rate of change in HPLC purity can be held to 0.10% or less when the storage condition is one of the following conditions: (4) a storage temperature of 0 C. or more and less than 25 C.; (5) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.5 to 7.4; and (6) a storage temperature of 40 C. or more and less than 60 C. and a crystal pH of 5.2 to 6.2.
[0039] Moreover, it became obvious that the rate of change in HPLC purity can be held to 0.05% or less when the storage condition is one of the following conditions: (7) a storage temperature of 0 C. or more and less than 25 C.; and (8) a storage temperature of 25 C. or more and less than 40 C. and a crystal pH of 4.6 to 6.6.